CHRS logo

CHRSCoherus Oncology Inc.

$1.51
$0.125
(7.94%)
Today
Closed $1.45
$0.06
(4.14%)
After Hours
Updated: 04:11 PM EDT
Mkt Cap$242.94M
Vol898,526.00
51

Neutral Sentiment

How do you feel about CHRS?

News
all
press releases
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth...
PR Newswire
News Placeholder
More News
News Placeholder
Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -38.89% and -14.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
Here is how AnaptysBio, Inc. (ANAB) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
Zacks
News Placeholder
Coherus Oncology (CHRS) Projected to Post Quarterly Earnings on Monday
Coherus Oncology (NASDAQ:CHRS) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-coherus-biosciences-inc-stock...
MarketBeat
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above 200-Day Moving Average - Here's Why
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above 200-Day Moving Average - What's Next...
MarketBeat
News Placeholder
Is Brookdale Senior Living (BKD) Outperforming Other Medical Stocks This Year?
Here is how Brookdale Senior Living (BKD) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
Zacks
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above Two Hundred Day Moving Average - Time to Sell?
Coherus Oncology (NASDAQ:CHRS) Shares Cross Above Two Hundred Day Moving Average - Should You Sell...
MarketBeat
News Placeholder
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Hold" by Brokerages
Coherus Oncology, Inc. (NASDAQ:CHRS - Get Free Report) has earned an average recommendation of "Hold" from the five research firms that are presently covering the firm, Marketbeat reports. One...
MarketBeat
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above 200 Day Moving Average - Should You Sell?
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above 200 Day Moving Average - Time to Sell...
MarketBeat
News Placeholder
Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know
Coherus Oncology (CHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
<
1
2
...
>

Advertisement|Remove ads.